CAM
RVMD icon

Cresset Asset Management’s Revolution Medicines RVMD Stock Holding History

Cresset Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-238,695
Closed -$8.31M – 801
2020
Q3 		$8.31M Buy
+238,695
New +$6.61M 0.16% 65

Other funds holding RVMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cresset Asset Management's RVMD Position: Q4 2020 in Review

Cresset Asset Management sold out of Revolution Medicines (RVMD) in Q4 2020, closing a stake of 238,695 shares — an estimated $8.31M sold.

Cresset Asset Management first reported a position in RVMD in Q3 2020 and held it in 1 quarter. The position peaked at $8.31M in Q3 2020. 119 funds tracked by Wall St. Rank hold RVMD as of Q4 2020.

  • Cresset Asset Management reported no remaining Revolution Medicines position as of Q4 2020 after selling out during the quarter.
  • Cresset Asset Management sold 238,695 Revolution Medicines shares in Q4 2020, an estimated $8.31M.
  • Cresset Asset Management first reported a position in Revolution Medicines in Q3 2020 and held it in 1 quarter.
  • Cresset Asset Management's Revolution Medicines position peaked at $8.31M in Q3 2020.
  • 119 funds tracked by Wall St. Rank held Revolution Medicines as of Q4 2020.

Based on Cresset Asset Management's 13F filing for Q4 2020, filed 11 Feb 2021.